Literature DB >> 22415625

[Gout as a systemic disease. Manifestations, complications and comorbidities of hyperuricaemia].

A-K Tausche1, B Manger, U Müller-Ladner, B Schmidt.   

Abstract

Of all inflammatory rheumatic diseases gout has the highest prevalence. Patients with intermittent acute gout attacks are usually treated by primary care physicians. However, in cases of insufficient long-term control of serum uric acid levels, complications or atypical clinical manifestations may necessitate consultation with a rheumatologist in the further course of the disease. An oligoarticular or polyarticular presentation can give rise to the initial suspicion of rheumatoid or psoriatic arthritis. In these cases a careful clinical work-up supported by laboratory and imaging investigations is necessary and synovial fluid analysis is usually required. As in other rheumatic diseases extra-articular manifestations are of utmost importance for morbidity and mortality. Gout is a complex metabolic and inflammatory disease and besides articular symptoms the renal and cardiovascular effects of hyperuricemia are particularly relevant for the overall prognosis.

Entities:  

Mesh:

Year:  2012        PMID: 22415625     DOI: 10.1007/s00393-011-0953-9

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  39 in total

1.  Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.

Authors:  Marian Goicoechea; Soledad García de Vinuesa; Ursula Verdalles; Caridad Ruiz-Caro; Jara Ampuero; Abraham Rincón; David Arroyo; José Luño
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-10       Impact factor: 8.237

2.  Disabling gout.

Authors:  A K Tausche; I Panzner; D Aust; C Wunderlich
Journal:  Lancet       Date:  2010-09-16       Impact factor: 79.321

3.  The influence of temperature on the solubility of monosodium urate.

Authors:  J N Loeb
Journal:  Arthritis Rheum       Date:  1972 Mar-Apr

4.  Intra-abdominal gout mimicking pelvic abscess.

Authors:  Chia-Hui Chen; Clement Kuen-Huang Chen; Lee-Ren Yeh; Huay-Ban Pan; Chien-Fang Yang
Journal:  Skeletal Radiol       Date:  2004-11-20       Impact factor: 2.199

5.  Rare coexistence of gouty and septic arthritis: a report of 14 cases.

Authors:  C-T Weng; M-F Liu; L-H Lin; M-Y Weng; N-Y Lee; A-B Wu; K-Y Huang; J-W Lee; C-R Wang
Journal:  Clin Exp Rheumatol       Date:  2009 Nov-Dec       Impact factor: 4.473

6.  Spontaneous rupture of the Achilles tendon in a patient with gout.

Authors:  P G Mahoney; P D James; C J Howell; A J Swannell
Journal:  Ann Rheum Dis       Date:  1981-08       Impact factor: 19.103

7.  Pancreatic gout masquerading as pancreatic cancer in a heart transplant candidate.

Authors:  Sachin Gupta; Zsuzsanna McMahan; Parag C Patel; David W Markham; Mark H Drazner; Pradeep P A Mammen
Journal:  J Heart Lung Transplant       Date:  2009-10       Impact factor: 10.247

8.  Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study.

Authors:  E W Campion; R J Glynn; L O DeLabry
Journal:  Am J Med       Date:  1987-03       Impact factor: 4.965

Review 9.  Gout--current diagnosis and treatment.

Authors:  Anne-Kathrin Tausche; Tim L Jansen; Hans-Egbert Schröder; Stefan R Bornstein; Martin Aringer; Ulf Müller-Ladner
Journal:  Dtsch Arztebl Int       Date:  2009-08-24       Impact factor: 5.594

10.  Tophaceous gout and renal insufficiency: a new solution for an old therapeutic dilemma.

Authors:  Anne-Kathrin Tausche; Carsten Wunderlich; Martin Aringer
Journal:  Case Rep Med       Date:  2011-05-14
View more
  6 in total

1.  As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.

Authors:  A-K Tausche; M Christoph; M Forkmann; U Richter; S Kopprasch; C Bielitz; M Aringer; C Wunderlich
Journal:  Rheumatol Int       Date:  2013-09-12       Impact factor: 2.631

Review 2.  [Evidence-based recommendations for diagnostics and treatment of gouty arthritis in the specialist sector : S2e guidelines of the German Society of Rheumatology in cooperation with the AWMF].

Authors:  U Kiltz; R Alten; M Fleck; K Krüger; B Manger; U Müller-Ladner; H Nüsslein; M Reuss-Borst; A Schwarting; H Schulze-Koops; A K Tausche; J Braun
Journal:  Z Rheumatol       Date:  2017-03       Impact factor: 1.372

3.  [Interleukin-1-mediated diseases].

Authors:  D Holzinger; H Becker; A M Jacobi
Journal:  Internist (Berl)       Date:  2013-04       Impact factor: 0.743

4.  Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey.

Authors:  Puja P Khanna; George Nuki; Thomas Bardin; Anne-Kathrin Tausche; Anna Forsythe; Amir Goren; Jeffrey Vietri; Dinesh Khanna
Journal:  Health Qual Life Outcomes       Date:  2012-09-22       Impact factor: 3.186

5.  Urate lowering therapy with febuxostat in daily practice-a multicentre, open-label, prospective observational study.

Authors:  Anne-Kathrin Tausche; Monika Reuss-Borst; Ute Koch
Journal:  Int J Rheumatol       Date:  2014-09-03

Review 6.  Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout.

Authors:  Romy Hansildaar; Daisy Vedder; Milad Baniaamam; Anne-Kathrin Tausche; Martijn Gerritsen; Michael T Nurmohamed
Journal:  Lancet Rheumatol       Date:  2020-09-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.